Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan

BACKGROUND: Recent data suggest that circulating endothelial and progenitor cells (CECs and CEPs, respectively) may have predictive potential in cancer patients treated with bevacizumab, the antibody recognizing vascular endothelial growth factor (VEGF). Here we report on CECs and CEPs investigated...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Cuppini, Lucia, Calleri, Angelica, Bruzzone, Maria Grazia, Prodi, Elena, Anghileri, Elena, Pellegatta, Serena, Mancuso, Patrizia, Porrati, Paola, Di Stefano, Anna Luisa, Ceroni, Mauro, Bertolini, Francesco, Finocchiaro, Gaetano, Eoli, Marica
פורמט: Artigo
שפה:Inglês
יצא לאור: Public Library of Science 2013
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3772091/
https://ncbi.nlm.nih.gov/pubmed/24069296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0074345
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים